Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2016 07:00 ET | Source: ProQR Therapeutics

ProQR to Present at Scientific and Investor Conferences in September

LEIDEN, the Netherlands, Sept. 06, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for...
August 17, 2016 07:00 ET | Source: ProQR Therapeutics

ProQR Announces Results for the Second Quarter of 2016

LEIDEN, the Netherlands, Aug. 17, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
July 19, 2016 07:00 ET | Source: ProQR Therapeutics

ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis

LEIDEN, the Netherlands, July 19, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
June 21, 2016 09:00 ET | Source: ProQR Therapeutics

ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC

LEIDEN, the Netherlands, June 21, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
June 01, 2016 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference

LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that the company will present pre-clinical data for QR-010 at the 39th European...
June 01, 2016 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation

LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the company’s investigational drug QR-110 has received orphan drug designation...
May 18, 2016 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Results for the First Quarter of 2016

LEIDEN, the Netherlands, May 18, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
April 25, 2016 16:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-110 for LCA10 at the 2016 ARVO Annual Meeting

LEIDEN, Netherlands, April 25, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that the company will present pre-clinical data for QR-110 which is being developed...
April 07, 2016 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Annual Meeting of Shareholders

LEIDEN, the Netherlands, April 07, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Annual General Meeting of Shareholders will be held on Tuesday, June 21,...
March 01, 2016 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Highlight a Growing Pipeline During a Research & Development Day and Present at the Barclays Global Healthcare Conference

LEIDEN, the Netherlands, March 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines...